Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Amino acid metabolism
研究概览
简要总结
The purpose of this study is to examine whether non-alcoholic fatty liver disease (NAFLD) is associated with hepatic glucagon resistance and hyperglucagonemia.
详细描述
Hyperglucagonemia is a common condition in obesity, prediabetes and type 2 diabetes. It increases the hepatic glucose production, thus contributing to type 2-diabetic hyperglycemia. In the current study we wish to examine whether non-alcoholic fatty disease (NAFLD) results in hepatic glucagon resistance. This could result in hyperglucagonemia through a feedback mechanism acting on the level of pancreatic alpha cells. Cirrhosis and type 1 diabetes, respectively, has previously been shown to be associated with hepatic glucagon resistance but it has not been examined in relation to NAFLD in humans so far.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Normal fasting plasma glucose and HbA1c < 6.0%
- •Between 18.5 and 25 kg/m2 or between 30 and 40 kg/m2
- •Normal haemoglobin
- •Normal coagulation factor II, VII and X, INR and thrombocytes
- •Age above 25 years
- •Informed consent
排除标准
- •Prediabetes (impaired glucose tolerance and/or impaired fasting plasma glucose)
- •First-degree relatives with diabetes
- •Nephropathy (eGFR < 60ml/min and/or albuminuria)
- •Liver disease (ALAT and/or serum ASAT >2x normal values)
- •Use of anticoagulative medicine like Clopidogrel og Warfarin
- •Pregnancy and/or breastfeeding
- •Age above 80 years
- •Any condition that the investigator feels would interfere with trial participation
研究组 & 干预措施
Healthy, lean
15 healthy, lean subjects.
Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed.
干预措施: Liver biopsy (Procedure)
Healthy, lean
15 healthy, lean subjects.
Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed.
干预措施: Pancreatic clamp (Other)
Obese, otherwise healthy
15 obese, otherwise healthy subjects
Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed.
干预措施: Liver biopsy (Procedure)
Obese, otherwise healthy
15 obese, otherwise healthy subjects
Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed.
干预措施: Pancreatic clamp (Other)
结局指标
主要结局
Amino acid metabolism
时间窗: 0-180 min
Endogenous glucose production
时间窗: 0-180 min
次要结局
- Degree of steatosis(baseline)
- Total RNA sequencing of liver biopsies(baseline)
研究者
Malte Palm Suppli
Research year assistant
University Hospital, Gentofte, Copenhagen